Nathanael Gray, PhD

Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Dana-Farber Cancer Institute
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Authors: Authors: Rusan M, Li K, Li Y, Christensen CL, Abraham BJ, Kwiatkowski N, Buczkowski KA, Bockorny B, Chen T, Li S, Rhee K, Zhang H, Chen W, Terai H, Tavares T, Leggett AL, Li T, Wang Y, Zhang T, Kim TJ, Hong SH, Poudel-Neupane N, Silkes M, Mudianto T, Tan L, Shimamura T, Meyerson M, Bass AJ, Watanabe H, Gray NS, Young RA, Wong KK, Hammerman PS.
Cancer Discov
View full abstract on Pubmed
The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists.
Authors: Authors: Vollmer S, Strickson S, Zhang T, Gray N, Lee KL, Rao VR, Cohen P.
Biochem J
View full abstract on Pubmed
Structure-guided development of covalent TAK1 inhibitors.
Authors: Authors: Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS.
Bioorg Med Chem
View full abstract on Pubmed
Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
Authors: Authors: Brown WS, Tan L, Smith A, Gray NS, Wendt MK.
Mol Cancer Ther
View full abstract on Pubmed
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Authors: Authors: Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J.
Cancer Res
View full abstract on Pubmed
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
Authors: Authors: Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M.
PLoS One
View full abstract on Pubmed
DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.
Authors: Authors: Huang Z, Tan L, Wang H, Liu Y, Blais S, Deng J, Neubert TA, Gray NS, Li X, Mohammadi M.
ACS Chem Biol
View full abstract on Pubmed
Discovery of type II inhibitors of TGFß-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).
Authors: Authors: Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS.
J Med Chem
View full abstract on Pubmed
Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.
Authors: Authors: Banerjee S, Buhrlage SJ, Huang HT, Deng X, Zhou W, Wang J, Traynor R, Prescott AR, Alessi DR, Gray NS.
Biochem J
View full abstract on Pubmed
What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule.
Authors: Authors: Rodon Ahnert J, Gray N, Mok T, Gainor J.
Am Soc Clin Oncol Educ Book
View full abstract on Pubmed